



SEP 29 2006

Mary K. VanAtten
Patent Department
Bristol-Myers Squibb Company
P.O. Box. 4000
Princeton, NJ 08543-4000In Re: Patent Term Extension
Application for
U.S. Patent No. 6,596,746
Filed: August 15, 2006

NOTICE OF INFORMALITIES

The above-identified application for patent term extension has been afforded a filing date and a request to determine eligibility of SPRYCEL® (dasatinib) has been sent to the Food and Drug Administration. However, Applicants have incorrectly identified the date of the last day for submission of the Patent Term Extension Application by more than one year and hence their statement regarding timely submission is incorrect (see page 2 of the application, complying with 37 CFR 1.740(a)(5)).

It is requested that the applicant for patent term extension supplement the original application to correctly identify the final date for submission of the patent term extension application and therefore make the appropriate statement about timely submission of the patent term extension application under 35 USC 156.

Applicant has **ONE MONTH** from the date of this letter in order to supplement the original filing and correct the noted error. Extensions of time under 37 CFR 1.136 are available.

Any correspondence from applicant with respect to this matter should be addressed as follows:

By mail: Assistant Commissioner for Patents
Box Patent Ext.
Washington, D.C. 20231

By FAX: (571) 273-0100
Attn: Office of Patent Legal Administration

Telephone inquiries related to this notice should be directed to the undersigned at (571) 272-7755.

Mary C. Till
Legal Advisor
Office of Patent Legal Administration
Office of the Deputy Commissioner
for Patent Examination Policy

cc: Office of Regulatory Policy
HFD-7
5600 Fishers Lane (Rockwall II Rm 1101)
Rockville, MD 20857

RE: SPRYCEL® (dasatinib)
FDA Docket No.: